PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-15.30%
Cash & equivalents declining -15.30% while CRVO's grows 631.62%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-15.30%
Below half of CRVO's 631.62%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.91%
0.75-0.9x CRVO's -21.03%. Bill Ackman would ask if competitor is building short-term resources more aggressively.
-12.74%
≥ 1.5x CRVO's -3.96%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.02%
Less than half of CRVO's 1060.67%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-1.64%
Below half of CRVO's 2.44%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-15.58%
≥ 1.5x CRVO's -7.70%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
72.22%
Above 1.5x CRVO's 25.04%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-79.94%
Similar yoy changes to CRVO's -99.81%. Walter Schloss finds parallel near-term liability trends.
32.21%
Less than half of CRVO's -85.60%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.21%
Less than half of CRVO's -77.63%. David Dodd sees far fewer liability expansions relative to competitor.
0.06%
Less than half of CRVO's -93.33%. David Dodd sees fewer share issuances vs. competitor.
-3.27%
Below half CRVO's 2.83%. Michael Burry suspects major net losses or high dividends vs. competitor.
0.51%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-24.85%
Below half CRVO's 233.98%. Michael Burry sees potential underperformance in building shareholder capital.
-15.58%
≥ 1.5x CRVO's -7.70%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.30%
Less than half of CRVO's -1153.22%. David Dodd sees better deleveraging or stronger cash buildup than competitor.